Skip to main content Skip to navigation Skip to search

Press releases

YearType

2024

17 Dec 2024, 21:40 | Regulatory

Hansa Biopharma announces positive full results from 15-HMedIdeS-09 Phase 2 study and comparative analysis of imlifidase in patients with Guillain-Barré Syndrome

5 Dec 2024, 15:30

Hansa Biopharma Completes Enrolment in Global Pivotal Phase 3 Trial of imlifidase in Anti-Glomerular Basement Membrane Disease

Data from the trial is expected to be shared in 2025

3 Dec 2024, 07:00

Genethon and Hansa Biopharma announce initiation of a Phase 2 trial of imlifidase as a pre-treatment to GNT-0003 in severe Crigler-Najjar syndrome

The trial will be conducted in patients with pre-existing anti-AAV antibodies which limit use of gene therapy treatment

13 Nov 2024, 09:00

Hansa Biopharma to Attend Jefferies London Healthcare Conference

30 Oct 2024, 09:00

Hansa Biopharma to Attend Truist Securities BioPharma Symposium

17 Oct 2024, 07:00 | Regulatory

Hansa Biopharma Reports Third Quarter and Interim January - September 2024 Financial Results

Q3 2024 marks highest ever in-market quarterly sales performance and fourth consecutive quarter of strong sales performance

7 Oct 2024, 10:00

Hansa Biopharma’s HNSA-5487 Achieved Rapid and Highly Robust IgG Reduction by More Than 95% and Clear Redosing Potential in First-in-Human Trial

3 Oct 2024, 07:00

Hansa Biopharma to host Q3 2024 interim results conference call

E-mail

Sign up to receive updates on the latest company news and filings